SCHEMBL5649196

SCHEMBL5649196

CC(C)COC(OCC(C)C)N(C)C

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4538748 0.77 ALDH1A1 (0.32) ALDH1A1
SCHEMBL9586122 0.72 FDPS (0.32)
SCHEMBL131012 0.69 THRB (0.44)
SCHEMBL1572578 0.67 LMNA (0.47) ALDH1A1
SCHEMBL1495313 0.67 THRB (0.41) ALDH1A1
SCHEMBL125895 0.67
SCHEMBL10574849 0.67 ALDH1A1 (0.38) ALDH1A1
SCHEMBL28532808 0.67
SCHEMBL3900511 0.65 ALDH1A1 (0.36) ALDH1A1
SCHEMBL24664648 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4276095-A2 PROCESSES FOR PREPARING ASK1 INHIBITORS Gilead Sciences, Inc. (US) 2023-11-15 EP disclosed
CN-112225699-B Process for preparing ASK1 inhibitors 吉利德科学公司 2023-11-14 CN disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed
EP-3693366-B1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES INC (US) 2023-06-28 EP disclosed
US-11685749-B2 C26-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2023-06-27 US disclosed
US-20230158158-A1 PYRAZOLO QUINAZOLINE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 UPPTHERA (KR) 2023-05-25 US disclosed
US-20230055672-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-02-23 US disclosed
US-20230038702-A1 BRIGHT TARGETABLE RED CA2+ INDICATORS HOWARD HUGHES MEDICAL INSTITUTE 2023-02-09 US disclosed
US-11364300-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2022-06-21 US disclosed
US-20220135527-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES, INC. 2022-05-05 US disclosed
CN-107108519-A Process for preparing ASK1 inhibitors 吉利德科学公司 2017-08-29 CN disclosed
US-20170233350-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES, INC. 2017-08-17 US disclosed
US-9586933-B2 Processes for preparing ASK1 inhibitors GILEAD SCIENCES, INC. (US) 2017-03-07 US disclosed
US-20160244430-A1 Processes for preparing ASK1 inhibitors GILEAD SCIENCES, INC. (US) 2016-08-25 US disclosed
WO-2016106384-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES, INC. (US) 2016-06-30 WO disclosed
US-7164029-B2 Process for the preparation of benzylimidazole derivatives DIPHARMA S.P.A. (IT) 2007-01-16 US disclosed
EP-1548009-A2 Process for the preparation of benzylimidazole derivatives and for losartan Dipharma S.p.A. (IT) 2005-06-29 EP disclosed
US-20050090672-A1 Process for the preparation of benzylimidazole derivatives DIPHARMA S.P.A. (IT) 2005-04-28 US disclosed
US-5213608-A Sulfonylguanidines BAYER AKTIENGESELLSCHAFT (DE) 1993-05-25 US disclosed
US-5167692-A Pre- and postemergence BAYER AKTIENGESELLSCHAFT (DE) 1992-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11685749-B2 C26-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR ALDH1A1 4742/4885
US-20230038702-A1 BRIGHT TARGETABLE RED CA2+ INDICATORS ATP2A2, ATP2A3, CACNB2 ALDH1A1 2321/4885
US-20170233350-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS MAP3K1, MAP3K6, MAP3K7 ALDH1A1 2697/4885
US-20050090672-A1 Process for the preparation of benzylimidazole derivatives REN, AGTR1, AGTR2 ALDH1A1 822/4885
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR ALDH1A1 4528/4885
US-11364300-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR ALDH1A1 4803/4885
US-20160244430-A1 Processes for preparing ASK1 inhibitors MAP3K1, MAP3K6, MAP3K7 ALDH1A1 2697/4885
US-20220135527-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS MAP3K1, MAP3K6, MAP3K7 ALDH1A1 2697/4885
US-20230055672-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR ALDH1A1 4803/4885
US-20230158158-A1 PYRAZOLO QUINAZOLINE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 PLK1, BUB1, BUB1B ALDH1A1 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.